CryoPort (CYRX) Set to Post Quarterly Earnings on Thursday

CryoPort (NASDAQ:CYRX) will likely be issuing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect CryoPort to post earnings of ($0.19) per share and revenue of $48.68 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 5:00 PM ET.

CryoPort (NASDAQ:CYRX) last released its earnings results on Thursday, August 6th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The firm had revenue of $48.97 million during the quarter, compared to the consensus estimate of $48.18 million. CryoPort had a negative return on equity of 7.20% and a negative net margin of 20.05%. On average, analysts expect CryoPort to post ($0.83) EPS for the current fiscal year and ($0.78) EPS for the next fiscal year.

CryoPort Price Performance

Shares of CYRX opened at $16.23 on Tuesday. The firm has a market cap of $822.05 million, a P/E ratio of -18.03 and a beta of 1.96. The stock has a 50 day simple moving average of $16.94 and a two-hundred day simple moving average of $13.34. CryoPort has a 1 year low of $7.61 and a 1 year high of $18.88.

Wall Street Analyst Weigh In

Several research firms have commented on CYRX. Piper Sandler raised shares of CryoPort to a “buy” rating in a research note on Tuesday, October 13th. Weiss Ratings raised shares of CryoPort from a “sell (d)” rating to a “hold (c-)” rating in a research note on Thursday, October 8th. Guggenheim upped their price objective on shares of CryoPort from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Robert W. Baird set a $26.00 target price on shares of CryoPort in a report on Tuesday, October 13th. Finally, BTIG Research increased their target price on shares of CryoPort from $25.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, October 13th. Eight equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $19.33.

Insider Buying and Selling at CryoPort

In other news, CEO Jerrell Shelton sold 28,800 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $14.91, for a total value of $429,408.00. Following the completion of the sale, the chief executive officer owned 1,201,814 shares of the company’s stock, valued at approximately $17,919,046.74. The trade was a 2.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 9.50% of the company’s stock.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) provides temperature-controlled supply chain solutions for the life sciences industry. The company supports the transportation, storage and management of biological materials, including cell and gene therapies, vaccines, biologics, reproductive materials and other temperature-sensitive products.

Its offerings include cryogenic and refrigerated shipping containers, biological material storage, transportation logistics, shipment monitoring and related supply chain management services.